Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380

12 november 2026 bijgewerkt door: Cascade Pharmaceuticals, Inc

A Randomized, Double-blind, Placebo-controlled, Sequential, Multiple Ascending Dose (MAD) Study Following Oral Administration in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380

A study in Healthy Participants with Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380.

Studie Overzicht

Toestand

Nog niet aan het werven

Gedetailleerde beschrijving

This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, PK and PD of CS060380 following oral multiple ascending dose administration in healthy participants with elevated LDL-C.

Approximately 30 participants (10 participants per cohort: n=8 participants will receive active CS060380 and n=2 participants will be administered placebo) will be enrolled sequentially in 3 ascending dose groups. The proposed dose levels will range from 1.0 mg to 4.0 mg.

The next higher dose cohort will be enrolled only after the prior dose cohort has been discharged from the CPC on Day 17 and the SRC has reviewed all available safety/tolerability, PK/PD, and thyroid function data.

Studietype

Ingrijpend

Inschrijving (Geschat)

30

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. The participant provided signed and dated informed consent.

  2. Male or female aged 18-65 years (inclusive).

  3. Fasting LDL-C >110 mg/dL (2.85 mmol/L) at screening.

  4. Female participants must meet one of the following:

    1. Postmenopausal status confirmed by follicle-stimulating hormone (FSH) testing, or
    2. Surgically sterile (medically documented), or
    3. If with childbearing potential, the participant must agree to use at least one highly effective contraceptive method in combination with an additional effective contraceptive method from study initiation until 3 months after the last dose, or
    4. Complete abstinence (if agreed by the participant).

    Male participants, even if surgically sterilized (e.g., vasectomy), must:

    1. Use effective barrier contraception and refrain from sperm donation throughout the study and for 3 months after the last dose, or
    2. Complete abstinence (if agreed upon by the participant). Refer to Section 9.4 for detailed contraceptive requirements.
  5. Normal renal function (estimated glomerular filtration rate [eGFR] ≥ 80 mL/min/1.73 m², calculated using the CKD-EPI equation).

  6. Good general health, as judged by the Investigator based on: medical/surgical history, complete physical examination, vital signs, laboratory tests, and 12-lead ECG results (all findings either normal or with no clinically significant abnormalities).

  7. No significant medical history; assessed to be in good general health at screening, with evaluations completed ≤ 28 days before the first dose.

  8. Willingness and ability to: Understand and comply with study procedures/restrictions, complete the trial as planned and communicate effectively with the Investigator.

Exclusion Criteria:

  1. Individuals with special dietary requirements unable to comply with standardized diets.

  2. Females who are pregnant or lactating, those with pregnancy plans within 3 months post-trial, or female participants with positive pregnancy tests during screening/baseline periods.

  3. Participants with febrile illness or active infection within 7 days prior to the first dose of the investigational drug.

  4. Participants with positive urine drug screening results.

  5. Participants with a history of drug/substance abuse within 5 years prior to the trial or positive drug screening at Day -1.

  6. Participants receiving lipid-lowering therapy or with LDL-C > 190 mg/dL, or those with a history of coronary artery disease, cardiac arrhythmias, unexplained syncope, or family history of sudden cardiac arrest.

  7. Participants with a history of QTc prolongation:

    1. QTcF ≥ 450 ms during screening;
    2. Hypocalcemia or family history of long QT syndrome;
    3. Use of QT/QTc-prolonging medications;
    4. ECG abnormalities deemed clinically significant by the Investigator.
  8. Tobacco or nicotine product use within 3 months prior to screening or during the study until discharge.

  9. Use of other investigational drugs within 40 days prior to enrollment or within ≥ 5 half-lives (whichever is longer).

  10. Positive infectious disease screening results during screening (HIV antibody, HBsAg, HCV antibody).

  11. Clinically significant laboratory abnormalities per Investigator judgment during screening.

  12. Presence of clinically significant hypertension, defined as systolic blood pressure (SBP) > 145 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg, at Screening or Admission.

  13. Blood loss > 50 mL within 40 days or > 500 mL within 56 days prior to dosing.

  14. Regular alcohol consumption (> 1 unit/day) within 1 month prior to screening or positive alcohol test at screening or admission. [1 unit = 150 mL wine, 360 mL beer, or 45 mL 40% alcohol]. Alcohol consumption within 48 hours predose or during CRU stays.

  15. Prescription/OTC medication use within 14 days prior to admission (Day -1) or ≥ 5 half-lives (whichever is longer); or use of any of the inhibitors or induces as listed in Appendix 1, CYP3A-, p-glycoprotein- (p-gp) or breast cancer resistance protein (BCRP)-modulating substances (e.g., herbs, grapefruit) within 14 days predose or ≥ 5 half-lives.

  16. Thyroid disease history or clinically significant thyroid test abnormalities.

  17. Hypersensitivity to thyroid medications.

  18. Conditions potentially affecting drug ADME (e.g., gastrectomy, cholecystectomy, inflammatory bowel disease).

  19. Clinically significant comorbidities (e.g., GI, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular diseases) that may compromise study conduct/interpretation or pose risks per Investigator assessment.

  20. Hypersensitivity to investigational drug components, specific allergy history (asthma, urticaria, eczema), or atopic predisposition (allergy to ≥ 2 drugs/foods like milk/pollen).

  21. Any condition deemed by the Investigator to jeopardize participant safety or study integrity.

  22. Abnormal thyroid function tests (total/free T3, total/free T4, TSH) beyond reference ranges during screening.

  23. Troponin > ULN during screening or Day -1 periods.

  24. Presence of any psychiatric disorder or impaired mental capacity that may compromise the ability to provide informed consent, affect the assessment of efficacy, or impair compliance with the study protocol.

  25. Any other condition that, in the opinion of the investigator, may jeopardize the safety of the subject or compromise the quality of the clinical study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: MAD Cohort 1: CS060380 1.0 mg

CS060380 1.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

CS060380 is administered orally once daily (QD)

Matching placebo is administered orally once daily (QD)

Andere namen:
  • CS060380 Placebo
Experimenteel: MAD Cohort 2: CS060380 2.0 mg

CS060380 2.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

CS060380 is administered orally once daily (QD)

Matching placebo is administered orally once daily (QD)

Andere namen:
  • CS060380 Placebo
Experimenteel: MAD Cohort 3: CS060380 4.0 mg

CS060380 4.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

CS060380 is administered orally once daily (QD)

Matching placebo is administered orally once daily (QD)

Andere namen:
  • CS060380 Placebo

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Adverse Events during the study period
Tijdsspanne: Baseline to Day28

To characterize the safety and tolerability of multiple doses of CS060380 in healthy participants

Baseline to Day28

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cmax
Tijdsspanne: Day1

Pharmacokinetics: Maximum concentration during a dosing interval

Day1
Tmax
Tijdsspanne: Day1 Day17

Pharmacokinetics: Time to maximum plasma concentration

Day1 Day17
t1/2
Tijdsspanne: Day1

Pharmacokinetics: Terminal elimination half-life

Day1
AUClast
Tijdsspanne: Day1

Pharmacokinetics: AUC from time 0 to the last measurable concentration

Day1
AUCinf
Tijdsspanne: Day1

Pharmacokinetics: area under the plasma concentration-time curve from time zero to infinity

Day1
CL/F
Tijdsspanne: Day1

Pharmacokinetics: apparent total plasma clearance

Day1
Cmax,ss
Tijdsspanne: Day14

Pharmacokinetics: steady-state maximum plasma concentration

Day14
Cmin
Tijdsspanne: Day14

Pharmacokinetics: minimum concentration during a dosing interval

Day14
t1/2,ss
Tijdsspanne: Day14

Pharmacokinetics: steady-state terminal elimination half-life

Day14
AUCτ (τ = 24 hours)
Tijdsspanne: Day14

Pharmacokinetics: AUC from time 0 to 24 hours after dosing

Day14
CL/Fss
Tijdsspanne: Day14

Pharmacokinetics: steady-State apparent total plasma clearance

Day14
DF
Tijdsspanne: Day14

Pharmacokinetics: degree of fluctuation

Day14
Cavg
Tijdsspanne: Day14

Pharmacokinetics: mean plasma concentration during a dosing interval

Day14
Rac_AUCτ
Tijdsspanne: Day14

Pharmacokinetics: accumulation ratio based on area under the plasma concentration-time curve

Day14

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
LDL-C
Tijdsspanne: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: low-density lipoprotein cholesterol

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
HDL-C
Tijdsspanne: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

Pharmacodynamics: high-density lipoprotein cholesterol

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
TG
Tijdsspanne: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: triglycerides

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
TC
Tijdsspanne: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: total cholesterol

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
SHBG
Tijdsspanne: Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: sex hormone binding globulin

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
Total/free T3
Tijdsspanne: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

To explore the effects on thyroid function parameters of CS060380

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
total/free T4,
Tijdsspanne: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

To explore the effects on thyroid function parameters of CS060380

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
TSH
Tijdsspanne: Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

To explore the effects on thyroid function parameters of CS060380

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Mary Purucker, MD, Pharmaron Clinical Pharmacology Center (CPC), Inc.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

15 maart 2027

Studie voltooiing (Geschat)

15 april 2027

Studieregistratiedata

Eerst ingediend

5 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • CS060380-MASH-US-I-05

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren